Showing results (1-10 of 2,332) with videos related to
Sort By:
Pageof 234
Cancer Treatment Reports|April 1, 1976
Biologic activity of two derivatives and six possible metabolites of cyclophosphamide (NSC-26271)P Lelieveld, L M van PuttenCancer Treatment Reports|February 1, 1979
The Princess Margaret Hospital study of ovarian cancer: stages I, II, and asymptomatic III presentationsA J Dembo, R S Bush, F A Beale, et al.Cancer Treatment Reports|April 1, 1979
Combined therapy for patients with mycosis fungoidesM L Griem, R P Tokars, V Petras, et al.Cancer Treatment Reports|September 1, 1979
An appraisal of the role of radiation therapy in the management of nonseminomatous germ-cell tumors of the testis in the era of effective chemotherapyM J PeckhamCancer Treatment Reports|March 1, 1976
Response to medroxyprogesterone acetate (NSC-26386) as secondary hormone therapy for metastatic breast cancer in postmenopausal womenD J Klaassen, E F Rapp, W E HirteCancer Treatment Reports|April 1, 1976
Studies on the in vivo formation of acrolein: 3-hydroxy-propylmercapturic acid as an index of cyclophosphamide (NSC-26271) activationR A AlarconCancer Treatment Reports|April 1, 1976
Cyclic phosphoramide mustard (NSC-69945) derivatives of amino acids and peptidesM SzekerkeCancer Treatment Reports|April 1, 1976
Stereochemistry, metabolism, and antitumor activity of 4-hydroperoxyisophosphamide (NSC-227114) and its stereoisomerA Takamizawa, T Iwata, K Yamaguchi, et al.Cancer Treatment Reports|April 1, 1976
Approaches to the pharmacokinetics of cyclophosphamide (NSC 26271): Quantitation of metabolitesI Jardine, R Brundrett, M Colvin, et al.Cancer Treatment Reports|April 1, 1976
Studies on 4-hydroperoxycyclophosphamide (NSC-181815): a simple preparation method and its application for the synthesis of a new class of "activated" sulfur-containing cyclophosphamide (NSC-26271) derivativesG Peter, T Wagner, H J HohorstPageof 234